Semaglutide
-
{
- All
- News
- Videos
- Web Stories
-
Are All Versions Of Semaglutide The Same? Doctor Answers
The original semaglutide was studied extensively in 50+ large-scale clinical trials and real-world settings, and has gathered 58 million patient years of exposure, providing insights into its long-term safety and efficacy, including effects on cardiovascular and metabolic health.
-
Ozempic, Wegovy And Zepbound May Cause Vision Loss? Indian Doctors Say Patients Need Not Panic
Reports link GLP-1 drugs like Ozempic and Wegovy to rare sudden vision loss called NAION, but doctors urge patients not to stop treatment without advice.
-
Novo Responds To GLP-1 Drug Ozempic Causing Vision Loss Claims: What Semaglutide Data Shows
Novo Nordisk says a large pooled analysis of clinical trials found no increased risk of rare NAION with semaglutide. Here is what the new evidence means for diabetes patients in India amid concerns over sudden vision loss.
-
Beyond Weight Loss: The Common And Rare Side Effects Of GLP-1 Medications Explained
While many people tolerate semaglutide well, the medicine can cause side effects ranging from temporary digestive problems to less common but potentially serious complications.
-
Ozempic, Wegovy, Zepbound Makers Sued In The US Over Sudden Blindness Risk
Dozens of patients are suing GLP-1 drugmakers over alleged sudden vision loss. The lawsuits cite a rare eye condition, while regulators and researchers continue to assess the possible link.
-
The Rise Of Unapproved GLP-1 Products And A Growing Patient Safety Concern
GLP-1 receptor agonists have transformed diabetes and obesity treatment, but high demand fuels a risky market for unapproved and counterfeit products.
-
Struggling With Asthma? New Study Says This Common Diabetes Drug May Reduce Severe Attacks By 40 Per Cent
The study has found that people with asthma who were prescribed semaglutide appeared to have nearly 40 per cent fewer asthma attacks compared to similar people taking another type of diabetes medicine.
-
Fatty Liver Disease Is Rising Fast And Most People Don't Know They Have It
As India continues to grapple with rising rates of obesity, diabetes and other metabolic disorders, fatty liver disease can no longer be viewed as a niche liver condition or a problem restricted to major cities.
-
DIY Peptide Injections Are Risky, And People May Make Serious Mistakes When Administering Them
DIY peptide injections for weight loss and muscle gain pose serious health risks due to lack of regulation and potential contamination.
-
Serena Williams Defends GLP-1 Weight-Loss Drug Use: What Doctors Want You To Know
Serena Williams used GLP-1 medication Zepbound to lose weight and improve health post-pregnancy, highlighting obesity treatment options.
-
Ozempic Users Warned Over Hair Loss Linked to Weight Loss Jabs
Doctors have warned that some people using Ozempic and similar weight loss injections may experience hair loss, with experts linking the issue to rapid weight loss and possible nutritional deficiencies rather than the medication itself.
-
Why Are Indians Quitting Weight-Loss Drugs Despite Lower Prices?
Generic GLP-1 drugs are cheaper than ever, but many Indians aren't staying on treatment. Here's why doctors say retention, not affordability, is the real challenge.
-
Taking Ozempic? New Study Explains Why Pairing It With Exercise Is Important For Your Muscles
Researchers found that combining semaglutide with regular exercise led to greater fat loss and better overall results than using the medication alone.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
Are All Versions Of Semaglutide The Same? Doctor Answers
The original semaglutide was studied extensively in 50+ large-scale clinical trials and real-world settings, and has gathered 58 million patient years of exposure, providing insights into its long-term safety and efficacy, including effects on cardiovascular and metabolic health.
-
Ozempic, Wegovy And Zepbound May Cause Vision Loss? Indian Doctors Say Patients Need Not Panic
Reports link GLP-1 drugs like Ozempic and Wegovy to rare sudden vision loss called NAION, but doctors urge patients not to stop treatment without advice.
-
Novo Responds To GLP-1 Drug Ozempic Causing Vision Loss Claims: What Semaglutide Data Shows
Novo Nordisk says a large pooled analysis of clinical trials found no increased risk of rare NAION with semaglutide. Here is what the new evidence means for diabetes patients in India amid concerns over sudden vision loss.
-
Beyond Weight Loss: The Common And Rare Side Effects Of GLP-1 Medications Explained
While many people tolerate semaglutide well, the medicine can cause side effects ranging from temporary digestive problems to less common but potentially serious complications.
-
Ozempic, Wegovy, Zepbound Makers Sued In The US Over Sudden Blindness Risk
Dozens of patients are suing GLP-1 drugmakers over alleged sudden vision loss. The lawsuits cite a rare eye condition, while regulators and researchers continue to assess the possible link.
-
The Rise Of Unapproved GLP-1 Products And A Growing Patient Safety Concern
GLP-1 receptor agonists have transformed diabetes and obesity treatment, but high demand fuels a risky market for unapproved and counterfeit products.
-
Struggling With Asthma? New Study Says This Common Diabetes Drug May Reduce Severe Attacks By 40 Per Cent
The study has found that people with asthma who were prescribed semaglutide appeared to have nearly 40 per cent fewer asthma attacks compared to similar people taking another type of diabetes medicine.
-
Fatty Liver Disease Is Rising Fast And Most People Don't Know They Have It
As India continues to grapple with rising rates of obesity, diabetes and other metabolic disorders, fatty liver disease can no longer be viewed as a niche liver condition or a problem restricted to major cities.
-
DIY Peptide Injections Are Risky, And People May Make Serious Mistakes When Administering Them
DIY peptide injections for weight loss and muscle gain pose serious health risks due to lack of regulation and potential contamination.
-
Serena Williams Defends GLP-1 Weight-Loss Drug Use: What Doctors Want You To Know
Serena Williams used GLP-1 medication Zepbound to lose weight and improve health post-pregnancy, highlighting obesity treatment options.
-
Ozempic Users Warned Over Hair Loss Linked to Weight Loss Jabs
Doctors have warned that some people using Ozempic and similar weight loss injections may experience hair loss, with experts linking the issue to rapid weight loss and possible nutritional deficiencies rather than the medication itself.
-
Why Are Indians Quitting Weight-Loss Drugs Despite Lower Prices?
Generic GLP-1 drugs are cheaper than ever, but many Indians aren't staying on treatment. Here's why doctors say retention, not affordability, is the real challenge.
-
Taking Ozempic? New Study Explains Why Pairing It With Exercise Is Important For Your Muscles
Researchers found that combining semaglutide with regular exercise led to greater fat loss and better overall results than using the medication alone.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
